Phase I/II evaluation of safety and efficacy of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct (Md-dnG1) as adjunctive intervention for superficial corneal opacity/corneal scarring

Hum Gene Ther. 2003 Feb 10;14(3):306-9.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Corneal Opacity / therapy*
  • Cyclin G
  • Cyclin G1
  • Cyclins / genetics*
  • Cyclins / metabolism
  • Dose-Response Relationship, Drug
  • Female
  • Genetic Vectors*
  • Humans
  • Male
  • Middle Aged
  • Retroviridae*

Substances

  • CCNG1 protein, human
  • Cyclin G
  • Cyclin G1
  • Cyclins